Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided audit content correctly cites that somnolence/sedation and dizziness occur more frequently than placebo and that patients should be observed for CNS depression when co-administered with sedative drugs. However, the surrounding list of statements includes several specifics (e.g., “up to 30%”, duration, timing after dose, and emphasis on high doses/underlying sleep disorders/fatigue) that are not supported by the supplied label excerpts.
Category Scores
Accurate Statements
Somnolence/sedation and dizziness are reported at a greater rate in NEURONTIN vs placebo in controlled epilepsy trials and in controlled post-herpetic neuralgia trials.
Label section 5.4 (epilepsy >12 years: somnolence 19% vs 9%, dizziness 17% vs 7%; post-herpetic neuralgia: somnolence 21% vs 5%, dizziness 28% vs 8%).
Patients should be carefully observed for CNS depression (somnolence and sedation) when NEURONTIN is used with other drugs with sedative properties, because of potential synergy.
Label section 5.4 (explicit monitoring/synergy guidance).
Unsupported Statements
According to the FDA label, gabapentin can cause drowsiness, fatigue, or lethargy in up to 30% of patients.
The provided label excerpts do not state a “up to 30%” figure for these terms.
Gabapentin-induced sleepiness can last from a few hours to an entire day.
The provided label excerpts do not describe duration of sleepiness after dosing.
The sleepiness associated with gabapentin peaks within 1-2 hours after administration.
The provided label excerpts do not provide a time-to-peak for sleepiness.
The sleepiness associated with gabapentin may last for up to 24 hours.
The provided label excerpts do not state a maximum duration (e.g., up to 24 hours) for sleepiness.
Drowsiness or fatigue from gabapentin is especially true if taken in high doses.
The provided label excerpt supports increased somnolence/dizziness at higher studied dose ranges, but does not support the specific framing that it is “especially true” for high doses.
Older age can contribute to increased sleepiness from gabapentin.
The provided geriatric excerpt discusses increased exposure and larger treatment effect in older (≥75) patients, but the excerpt does not state increased sleepiness specifically.
Underlying sleep disorders or fatigue can contribute to increased sleepiness from gabapentin.
The provided label excerpts do not mention underlying sleep disorders or fatigue as contributors.
Contradictions
Important Omissions
If the intent was to support the claim about co-administration with sedatives/synergy, the excerpts also mention morphine-related concentration increases and possible need for dose adjustment; this specific interaction detail was not included in the audit’s cited claim.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The core, label-supported warning is correctly conveyed (CNS depression monitoring with sedatives due to potential synergy). Unsupported timing/duration and “up to 30%” quantification could mislead monitoring expectations but do not directly negate the main safety message.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several ancillary statements in the provided list include specific numeric and temporal assertions (e.g., “up to 30%”, duration/peak timing) that are not supported by the supplied FDA label excerpts.
Suggested Improvement
Restrict statements to the label-supported content shown in section 5.4 and the geriatric excerpt (e.g., increased rates vs placebo and monitoring for CNS depression with sedative drugs), and remove or rephrase unsupported specifics about percentage, timing, and duration.